First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

被引：2
|
作者：
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] European Inst Oncol, Milan, Italy
[3] EOS SpA, Milan, Italy
[4] SENDO, Milan, Italy
[5] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS149
引用
收藏
页数：1
相关论文
共 50 条
  • [31] FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)
    von Tresckow, B.
    Goebeler, M. E.
    Sayehli, C.
    Gundermann, S.
    Eichenauer, D.
    Aulitzky, W.
    Bacchus, L.
    Igel, S.
    Schwab, M.
    Sasse, S.
    Hauns, B.
    Mais, A.
    Hentsch, B.
    Kohlhof, H.
    Krauss, R.
    Krauss, B.
    Baumgartner, R.
    Vitt, D.
    Engert, A.
    HAEMATOLOGICA, 2014, 99 : 711 - 711
  • [32] First-in-human study of PM14 in patients with advanced solid tumors.
    Vieito, Maria
    Aix, Santiago Ponce
    Paz-Ares, Luis G.
    Bahleda, Rastilav
    Massard, Christophe
    Agreda, Leyre
    Banus, Eva
    Fernandez, Cristian Marcelo
    Cristoveanu, Elena Y.
    Corral, Gema
    Llanero, Lourdes
    Lubomirov, Rubin
    Kahatt, Carmen Maria
    Fudio, Salvador
    Nieto, Antonio
    Cullell-Young, Martin
    Zeaiter, Ali Hassan
    Oberoi, Honey Kumar
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
    Dienstmann, Rodrigo
    Lassen, Ulrik
    Cebon, Jonathan
    Desai, Jayesh
    Brown, Michael P.
    Evers, Stefan
    Su, Fei
    Zhang, Weijiang
    Boisserie, Frederic
    Lestini, Brian
    Schostack, Kathleen
    Meresse, Valerie
    Tabernero, Josep
    TARGETED ONCOLOGY, 2016, 11 (02) : 149 - 156
  • [34] First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
    Rodrigo Dienstmann
    Ulrik Lassen
    Jonathan Cebon
    Jayesh Desai
    Michael P. Brown
    Stefan Evers
    Fei Su
    Weijiang Zhang
    Frederic Boisserie
    Brian Lestini
    Kathleen Schostack
    Valerie Meresse
    Josep Tabernero
    Targeted Oncology, 2016, 11 : 149 - 156
  • [35] Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Patnaik, Amita
    Rasco, Drew Warren
    Chambers, Glenda
    Beeram, Murali
    Savage, Ronald
    Hall, Terence
    Schwartz, Brian E.
    Kazakin, Julia
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] First-in-man phase 1 study of TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
    Doi, T.
    Yoh, K.
    Shitara, K.
    Takahashi, H.
    Ueno, M.
    Ohkawa, S.
    Morimoto, M.
    Kobayashi, S.
    Okusaka, T.
    Ueno, H.
    Morizane, C.
    Shiba, S.
    Furuse, J.
    Nagashima, F.
    Naruge, D.
    Okano, N.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S120 - S120
  • [37] First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients FGFR genoinically activated advanced solid tumors
    Voss, Martin Henner
    Adamo, Barbara
    Heist, Rebecca Suk
    Gandhi, Leena
    Moulon, Corinne
    Tanaka, Hiroaki
    Ishii, Nobuya
    Vasiln, Anne
    Aoki, Yuko
    Nicolas-Metral, Valerie
    Brienza, Silvan
    Zanna, Claudio
    Flaherty, Keith
    Tabernero, Josep
    Baseiga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.
    Horn, Leora
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather A.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Liang, Chris
    Harrow, Kimberly
    Gibbons, Jay
    Lovly, Christine Marie
    Pao, William
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
    Rodon, J.
    Peltola, K.
    Azaro, A.
    Alvarez, E. Castanon
    Garratt, C.
    Leskinen, H.
    Bjorklund, H.
    Ruck, A.
    Massard, C.
    Bono, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients
    Ma, Wen Wee
    Xie, Hao
    Fetterly, Gerald
    Pitzonka, Laura
    Whitworth, Amy
    LeVea, Charles
    Wilton, John
    Mantione, Krystin
    Schihl, Sarah
    Dy, Grace K.
    Boland, Patrick
    Iyer, Renuka
    Tan, Wei
    Brady, William
    Straubinger, Robert M.
    Adjei, Alex A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (02): : 184 - 189
12345